fexofenadine / Generic mfg. - LARVOL DELTA

Formulation, evaluation and characterization of fexofenadine IR and paracetamol SR multiparticulate drug delivery system. (PubMed, Pak J Pharm Sci) - "The research effectively demonstrated that preparing a single-unit dosage form of paracetamol and fexofenadine is a safe, simple and promising technique for SR of Paracetamol, thereby increasing patient compliance by reducing the dosage frequency."

Journal • Allergic Rhinitis • Immunology • Inflammation

Fexofenadine-Induced Pill Impaction Revealing Occult Eosinophilic Esophagitis With Incidental HPV-Related Esophageal Papilloma (ACG 2026) - "Image on the right papillomatous appearing lesion in the proximal Esophagus. Figure: Endoscopic examination of the proximal esophagus reveals findings consistent with active eosinophilic esophagitis, characterized by diffuse white exudates, mucosal edema with loss of the normal vascular pattern, and subtle longitudinal furrowing."

Eosinophilic Esophagitis • Gastrointestinal Disorder • Human Papillomavirus Infection • Immunology • Infectious Disease • Inflammation

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials."

Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Tamoxifen Therapy Is Associated With Altered Intestinal P-Glycoprotein Activity In Vivo. (PubMed, J Clin Pharmacol) - "This study evaluated intestinal P-gp activity in women receiving tamoxifen therapy using fexofenadine (FEXO) as a probe substrate. The observed pharmacokinetic profile is consistent with reduced oral bioavailability and suggests modulation of intestinal transporter-mediated drug disposition during tamoxifen therapy. These findings may have implications for the disposition of concomitantly administered orally administered P-gp substrates and warrant further investigation in dedicated clinical pharmacology studies."

Journal • Preclinical

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial (clinicaltrials.gov) - P2 | N=152 | Recruiting | Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2026 ➔ Dec 2027 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Infarction

Dual-site TAS2R14 binding by (-)-epicatechin gallate: A computational framework for neuroprotective drug repurposing. (PubMed, J Mol Graph Model) - "Furthermore, fexofenadine and ezetimibe showed favorable binding stability at the extracellular and intracellular sites, respectively. As this study is purely computational, experimental validation through receptor activation assays and relevant biological models will be required to determine whether the predicted binding interaction translates into functional modulation of TAS2R14 and therapeutic benefit. Nevertheless, these findings provide a computational foundation for prioritizing candidate TAS2R14 ligands and support future experimental studies to evaluate receptor activation, specificity, selectivity, and therapeutic efficacy, particularly for (-)-epicatechin gallate, in the context of TAS2R14-targeted neuroprotective drug repositioning."

Journal • CNS Disorders • Inflammation • TAS2R1

Allegra Franchino. (PubMed, Angew Chem Int Ed Engl) - ""I chose chemistry as a career because I was fascinated by its alphabet of formulae and grammar of curly arrows… The most challenging part of my job is managing people so that everyone can express their maximum potential…" Find out more about Allegra Franchino in her Introducing… Profile."

Journal

Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistamines? (PubMed, Cell Signal (Middlet)) - "Fexofenadine, an H1-antihistamine, decreased pancreas tumor size and altered expression of cancer relevant genes in a mouse model of PDAC...Studies are needed to determine if H1-antihistamines can augment anti-tumor response by current therapeutics and improve outcomes for PDAC patients. These findings with HRH1 suggest that other differentially expressed GPCRs with approved drugs may be therapeutic targets for PDAC and other cancers."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Discovery of Potent Antimalarial Agents Targeting Plasmodium falciparum DNA Gyrase B by Integrating Computational and Experimental Approaches. (PubMed, Chem Biol Drug Des) - "UNC8153 and Fexofenadine hydrochloride demonstrated time-dependent antiplasmodial activity, with lower IC50 values at 96 h than at 48 h under prolonged exposure conditions...Structural similarity analysis indicated that the identified compounds are chemically distinct from currently used antimalarial drugs, supporting their structural novelty. Collectively, these findings identify UNC8153 as a structurally distinct new antiplasmodial scaffold warranting further mechanistic, pharmacological, and in vivo evaluation."

Journal • Infectious Disease • Malaria

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin (clinicaltrials.gov) - P1 | N=62 | Completed | Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Recruiting ➔ Completed

Trial completion

The incidence of sleepiness in newer-generation antihistamine users: a systematic review and network meta-analysis. (PubMed, Eur J Clin Pharmacol) - "All nonsedating antihistamines administered at their usual doses have a higher prevalence of sleepiness compared to the placebo. However, most of the prevalence values are not statistically different from those of the placebo."

Clinical • Journal • Retrospective data • Review

A hybrid phenomenological finite element model of transcatheter aortic valve leaflet behaviour under non-circular annular deployment: in vitro validation and biomechanical insights. (PubMed, Biomech Model Mechanobiol) - "In this study, we present a finite element (FE) framework of a 27 mm Allegra TAV that reproduces the complete model, including stent and pericardial skirt and leaflets...Each geometry was evaluated in two limiting orientations of the ellipse's major axis (0 and 90 ) to analyse the model response in terms of valve coaptation. These results identify annular geometry and alignment as major factors in valve leaflet coaptation asymmetry and this asymmetry was found to correlate with increased stress concentration, which could compromise long-term valve function."

Journal • Preclinical

Acquired reactive perforating collagenosis in a patient with multiple comorbidities: a case report from Palestine. (PubMed, Front Med (Lausanne)) - "The patient was treated with the Dermovate scalp application, S.C. omalizumab administered monthly, fexofenadine hydrochloride, and body moisturizers. This case highlights the potential coexistence of ARPC with various systemic comorbidities, underscoring the need for comprehensive clinical assessment and exploration of underlying diseases in affected individuals. Furthermore, it highlights the importance of increased clinical awareness, particularly among physicians in similar settings, to consider ARPC in the differential diagnosis of pruritic cutaneous eruptions, especially in patients with associated comorbidities such as diabetes mellitus and chronic kidney disease."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Dermatology • Diabetes • Diabetic Nephropathy • Endocrine Disorders • Heart Failure • Metabolic Disorders • Nephrology • Pruritus • Renal Disease • Type 2 Diabetes Mellitus

Pregnancy Outcome Following First-Trimester Exposure to Bilastine: A Comparative Observational Cohort Study from the Israeli Teratology Information Service. (PubMed, J Clin Med) - "Pregnancy outcomes were compared with fexofenadine-exposed pregnancies. This cohort study, although small, provides preliminary reassurance for counseling regarding inadvertent early pregnancy exposure to bilastine. Larger studies are needed to validate these findings."

Journal • Observational data

Fexofenadine Induces ROS-Dependent Mitochondrial Dysfunction and Suppresses PI3K/AKT and MAPK Signaling in Cervical and Lung Cancer Cells. (PubMed, Cancers (Basel)) - "Fexofenadine disrupts redox homeostasis and is associated with reduced activation of pro-survival signaling pathways, resulting in oxidative stress-associated mitochondrial dysfunction and apoptosis in cancer cells. These findings provide mechanistic support for further evaluation of fexofenadine as a candidate for anticancer drug repurposing, while additional pharmacokinetic and in vivo studies are required to determine its translational relevance."

Journal • Cervical Cancer • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor • BCL2 • CASP3 • CASP7

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (clinicaltrials.gov) - P3 | N=284 | Recruiting | Sponsor: Sanofi | N=208 ➔ 284 | Trial completion date: Oct 2025 ➔ Aug 2027 | Trial primary completion date: Mar 2025 ➔ Jun 2027

Enrollment change • Trial completion date • Trial primary completion date • Dermatology • Pruritus

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (clinicaltrials.gov) - P3 | N=208 | Recruiting | Sponsor: Sanofi

New P3 trial • Dermatology • Pruritus

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (clinicaltrials.gov) - P3 | N=208 | Recruiting | Sponsor: Sanofi | Trial completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Dermatology • Pruritus

An oxygen-permeable, stirrer-pump-integrated liver-heart microphysiological system enables time-resolved analysis in PK-PD relationships of metabolism-dependent cardiotoxicity. (PubMed, NAM J) - "Drug concentration analysis by LC-MS/MS showed a marked increase in the formation of the primary metabolite fexofenadine, in the co-culture system, which was consistent with the reduced cardiotoxic potential of this metabolite...This proof-of-concept approach suggests a potential improvement in the translational predictability of human-relevant, metabolism-dependent cardiotoxicity by enabling integrated evaluation of pharmacokinetic and pharmacodynamic responses. These findings highlight the utility of this system as a simple and scalable alternative to conventional perfusion-based MPS."

Journal • PK/PD data • Cardiovascular • CYP3A4

A HRH1-YAP1 feedback loop drives pancreatic cancer progression and predicts therapeutic response. (PubMed, Oncol Lett) - "Patients in the high-risk group exhibited characteristics associated with worse outcomes, including KRAS mutations, chemoresistance, an immunosuppressive microenvironment and reduced responsiveness to immunotherapy. The present study establishes HRH1 as a novel therapeutic target in PDAC and proposes the repurposing of fexofenadine as a promising strategy to disrupt the oncogenic HRH1-YAP1 feedback loop."

IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • ECT2 • ITGA2 • ITGB5 • KRAS • MAML2 • SHCBP1 • YAP1 • YWHAZ

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom. (PubMed, Adv Ther) - "This study confirmed the environmental aspect of the triple value of self-care (social, economic, and environmental), by showcasing how self-care can help to reduce greenhouse gas emissions by the healthcare system in the UK."

Journal • Allergic Rhinitis • Allergy • Critical care • Immunology • Inflammation

Not so innocent after all: H1-antihistamine-induced Fixed Drug Eruption confirmed by lesional Patch Testing (BAD 2026) - "H1-antihistamines can be grouped by chemical structure into alkylamines (chlorphenamine), piperazines (hydroxyzine and cetirizine) and piperidines (loratadine and fexofenadine)...Symptoms persisted despite oral prednisolone but improved rapidly after stopping antihistamines...Repeat patch testing with fexofenadine and diphenhydramine is planned to assess cross-sensitivity. This case describes a rare antihistamine-associated fixed drug eruption with postulated class-related crossreactivity in a presumed safe drug class and highlights in situ patch testing as a safe diagnostic tool."

Immunology • Inflammation • Urticaria

Diagnostic challenge of chronic urticarial vasculitis: unmasking VEXAS syndrome in an older man (BAD 2026) - "He was empirically treated for discoid eczema or prebullous pemphigoid with topical corticosteroids and fexofenadine, achieving partial benefit...Systemic prednisolone led to rapid improvement of the rash, and subsequent treatment with erythropoietin, low-dose prednisolone and colchicine achieved sustained control of rash, resolution of systemic inflammation and normalization of haemoglobin...VEXAS should be considered in older men with chronic or refractory urticarial vasculitis, systemic inflammation and unexplained macrocytic anaemia. Early haematology assessment with bone marrow examination and UBA1 testing may reduce diagnostic delay."

Atopic Dermatitis • Dermatology • Dermatopathology • Herpes Zoster • Immunology • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Urticaria • Varicella Zoster • Vasculitis

Not so innocent after all: H1-antihistamine-induced Fixed Drug Eruption confirmed by lesional Patch Testing (BAD 2026) - "H1-antihistamines can be grouped by chemical structure into alkylamines (chlorphenamine), piperazines (hydroxyzine and cetirizine) and piperidines (loratadine and fexofenadine)...Symptoms persisted despite oral prednisolone but improved rapidly after stopping antihistamines...Repeat patch testing with fexofenadine and diphenhydramine is planned to assess cross-sensitivity. This case describes a rare antihistamine-associated fixed drug eruption with postulated class-related crossreactivity in a presumed safe drug class and highlights in situ patch testing as a safe diagnostic tool."

Immunology • Inflammation • Urticaria

Evaluation of the efficacy and safety of capivasertib in ER-positive, HER2-negative advanced or recurrent breast cancer. (JBCS 2026) - "History of fulvestrant treatment (+):18 cases...Although some adverse events were observed, in the latter 7 cases, early dermatological intervention and supportive medication (fexofenadine, PSL 2mg oral administration) prevented hospitalization...In conclusion, the effectiveness of Capivasertib in our clinical practice was reproducible from clinical trial results. Adverse events were minimized through careful management of supportive medications."

Clinical • Metastases • Breast Cancer • Diabetes • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2